These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 26833513)

  • 21. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
    Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
    Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group.
    Sköld CM; Bendstrup E; Myllärniemi M; Gudmundsson G; Sjåheim T; Hilberg O; Altraja A; Kaarteenaho R; Ferrara G
    J Intern Med; 2017 Feb; 281(2):149-166. PubMed ID: 27862475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current approaches to the management of idiopathic pulmonary fibrosis.
    Raghu G; Richeldi L
    Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Idiopathic Pulmonary Fibrosis].
    Prasse A
    Pneumologie; 2015 Oct; 69(10):608-14; quiz 615. PubMed ID: 26444136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammation and immunity in IPF pathogenesis and treatment.
    Heukels P; Moor CC; von der Thüsen JH; Wijsenbeek MS; Kool M
    Respir Med; 2019 Feb; 147():79-91. PubMed ID: 30704705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The therapy of idiopathic pulmonary fibrosis: what is next?
    Somogyi V; Chaudhuri N; Torrisi SE; Kahn N; Müller V; Kreuter M
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31484664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
    Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
    Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
    Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
    Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications.
    Nair GB; Matela A; Kurbanov D; Raghu G
    Expert Rev Respir Med; 2016 Jun; 10(6):699-711. PubMed ID: 27094006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe idiopathic pulmonary fibrosis: what can be done?
    Caminati A; Cassandro R; Torre O; Harari S
    Eur Respir Rev; 2017 Sep; 26(145):. PubMed ID: 28954763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ATP-induced fibrogenic pathway in circulating cells obtained by idiopathic pulmonary fibrotic (IPF) patients is not blocked by nintedanib and pirfenidone.
    Colarusso C; Falanga A; Di Caprio S; Terlizzi M; D'Andria E; Antonio M; Maiolino P; Sorrentino R
    Biomed Pharmacother; 2024 Jul; 176():116896. PubMed ID: 38876049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel approaches to pulmonary fibrosis.
    Jenkins G; Goodwin A
    Clin Med (Lond); 2014 Dec; 14 Suppl 6():s45-9. PubMed ID: 25468919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review.
    Antoniou K; Kamekis A; Symvoulakis EK; Kokosi M; Swigris JJ
    Curr Opin Pulm Med; 2020 Sep; 26(5):457-463. PubMed ID: 32701673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
    Spagnolo P; Maher TM; Richeldi L
    Pharmacol Ther; 2015 Aug; 152():18-27. PubMed ID: 25946646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment.
    Martinez FJ; Flaherty KR
    Chest; 2017 May; 151(5):1173-1174. PubMed ID: 28483105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
    Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
    J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
    Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
    Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.